The Pfizer trial is using the National Institute o
Post# of 148112
As you can see Pfizer even excludes the high moderates (score 5) on the WHO scale. Leronlimab's inclusion/exclusion criteria match up with 5 or 6 on the WHO scale. So completely different patient parameters. For supplemental oxygen at any point it's irrelevant to the Pfizer trial enrollment because any patients with supplemental oxygen are excluded if they are on it from the first day of their potential drug use.